News Cyxone AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 11:05:53 2024-04-26 am EDT			5-day change	1st Jan Change
0.0928 ^SEK	-4.33%		+6.91%	-7.57%

Apr. 22	Sweden's Cyxone Appoints New CEO	MT
Apr. 22	Cyxone AB Announces Chief Executive Officer Changes	CI

Sweden's Cyxone Appoints New CEO	Apr. 22	MT
Kjell Stenberg new CEO in Cyxone AB	Apr. 22	AQ
Cyxone AB Announces Chief Executive Officer Changes	Apr. 22	CI
BioStock: Cyxone comments on the clinical collaboration in the UK	Mar. 28	AQ
Cyxone Enters Research Deal for Rheumatoid Arthritis Therapy	Mar. 25	MT
Cyxone enters important research collaboration	Mar. 25	AQ
Cyxone Enters Important Research Collaboration with University of Glasgow	Mar. 25	CI
BioStock: Cyxone's CEO gives a status update	Mar. 05	AQ
Cyxone AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
BioStock: Cyxone identifies target protein for rabeximod	Jan. 17	AQ
Cyxone reaches important milestone regarding mechanism of action	Jan. 15	AQ
Cyxone Reaches an Important Milestone for the Drug Candidate Rabeximod	Jan. 15	CI
Cyxone welcomes a renewed engagement by Professor Rikard Holmdahl as Scientific Advisor	Nov. 20	AQ
Interim Report 1 January to 30 September 2023	23-10-27	AQ
Cyxone AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-27	CI
Cyxone to Receive Unitary Patent in EU for T20K Drug Candidate	23-10-09	MT
Cyxone receives Intention to Grant from the European Patent Office for a unitary patent of T20K	23-10-09	AQ
BioStock Investor Meeting: Cyxone	23-09-27	AQ
Interim Report 1 January to 30 June 2023	23-08-30	AQ
Cyxone AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI

No results for this search